Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens. More specifically, the present invention is directed to the use of a second generation anti-androgen compound, such as the compound 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide in the manufacture of a medicament for treating non-metastatic castration-resistant prostate cancer in a male human who previously received a first generation anti-androgen, wherein the compound is used in combination with a gonadotropin-releasing hormone (GnRH) agonist or orchiectomy.
